ELI LILLY AND COMPANY

Biopharma

Latest filing Jan 15, 2026

pharmaceuticals

$22.7M

Reported income

Consumer Issues/Safety/Products leads by disclosed activity

Filings

Most recent on Jan 15, 2026

Clients represented

ELI LILLY AND COMPANY leads by reported income

Lobbyists employed

ASKIA SURUMA appears most prominently

$628K

Contribution spend

Jason Smith leads among recipients

Reported Income Over Time

Annual totals based on disclosed filing amounts.

2025

$20.5M7 filings

2026

$2.2M1 filings

Client Portfolio

The clients this firm represents, ranked by disclosed filing amounts.

ELI LILLY AND COMPANY

Biopharma

8 filingsLatest Jan 15, 2026

$22.7M

Lobbyists Employed

Lobbyists are ranked by appearances and an equal share of each filing's reported amount.

ASKIA SURUMA

8 appearances8 filingsLatest Jan 15, 2026

What They Lobby On

Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.

Consumer Issues/Safety/Products

CSP

8 mentions8 filingsLatest Jan 15, 2026

$3.2M

apportioned income

Commerce, Dept of (DOC)8Executive Office of the President (EOP)8Health & Human Services, Dept of (HHS)8HOUSE OF REPRESENTATIVES

Government Touchpoints

The entities named in disclosed activities are the clearest available signal for where the firm is directing attention.

01HOUSE OF REPRESENTATIVES

56 mentions

02SENATE

56 mentions

03Executive Office of the President (EOP)

24 mentions

04U.S. Trade Representative (USTR)

16 mentions

Contribution Recipients

Officials who received contribution dollars disclosed by this firm.

Total contributions

$628K

Contribution items

239

Officials reached

125

01Jason Smith

Representative • Missouri

$16K

4 items

02Christopher A. Coons

Senator • Delaware

Industry Profile

AI-classified industry allocation based on the firm's filing activity.

Confidence

94%

Industry count

Biopharma

90%

Healthcare

10%

Registrant industry was derived from a single labeled client relationship.

Recent Filings

The latest disclosures filed by this firm.

ELI LILLY AND COMPANYQ4

2025 fourth quarter7 issues11 lobbyists

Medicare/MedicaidCopyright/Patent/TrademarkTrade (domestic/foreign)

$2.2M

Jan 15, 2026

ELI LILLY AND COMPANY2A

ELI LILLY AND COMPANY

Reported Income Over Time

Client Portfolio

Lobbyists Employed

What They Lobby On

Consumer Issues/Safety/Products

Government Touchpoints

Contribution Recipients

Industry Profile

Recent Filings

Copyright/Patent/Trademark

Health Issues

Medicare/Medicaid

Pharmacy

Taxation/Internal Revenue Code

Trade (domestic/foreign)